Amantadine increases the extracellular dopamine levels in the striatum by re-uptake inhibition and by N-methyl-d-aspartate antagonism
Authors:
- 1 October 1994
- journal article
- research article
- Published by Elsevier in Brain Research
- Vol. 662 (1-2) , 255-258
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Antiparkinsonian drugs and in vitro excitotoxicityBrain Research, 1992
- Extracellular dopamine in striatum: Influence of nerve impulse activity in medial forebrain bundle and local glutamatergic inputNeuroscience, 1992
- Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain studyEuropean Journal of Pharmacology: Molecular Pharmacology, 1991
- NMDA receptors and in vivo dopamine release in the nucleus accumbens and caudatusEuropean Journal of Pharmacology, 1990
- Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channelsEuropean Journal of Pharmacology, 1989
- Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortexEuropean Journal of Pharmacology, 1989
- Ketamine and phencyclidine cause a voltage-dependent block of responses to l-aspartic acidNeuroscience Letters, 1985
- Inhibition of [3H]dopamine accumulation in rat striatal synaptosomes by psychotropic drugsBiochemical Pharmacology, 1978
- Biochemical differentiation of amphetaminevsmethylphenidate and nomifensine in ratsJournal of Pharmacy and Pharmacology, 1977
- Evaluation of amantadine as a releasing agent or uptake blocker for H3-dopamine in rat brain slicesEuropean Journal of Pharmacology, 1972